VKTX Stock Catalyst: Viking Therapeutics Announced Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735

Sep 22, 2026 · 7:04am ET

The study demonstrated the promise of multiple maintenance dosing regimens.

Max move

+45.9%

High of day $45.93

Sparker timei

7:04am ET

VKTX · Sep 22, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Viking Therapeutics, Inc. (Nasdaq: VKTX) announced positive topline results from a maintenance study of their GLP-1/GIP agonist VK2735. The study aimed to evaluate the efficacy and safety of multiple maintenance dosing regimens.

The results demonstrated the promise of these regimens, indicating potential benefits for patients. The company plans to further analyze the data and discuss next steps for the development of VK2735.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time VKTX sparks.

Download Sniper App →

Catch the next VKTX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →